Pumafentrine

• CAT Number: I035211
• CAS Number: 207993-12-2
• Molecular Formula: C29H39N3O3
• Molecular Weight: 477.64
• Purity: 98%
• Synonyms: Pumafentrine; BY343; BYK 33043; BY-343; BYK33043
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-((4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl)-N,N-diisopropylbenzamide
• InChI: InChI=1S/C29H39N3O3/c1-8-35-27-15-22-23(16-26(27)34-7)28(30-25-13-14-31(6)17-24(22)25)20-9-11-21(12-10-20)29(33)32(18(2)3)19(4)5/h9-12,15-16,18-19,24-25H,8,13-14,17H2,1-7H3/t24-,25-/m1/s1
• InChIKey: CVDXFPBVOIERBH-JWQCQUIFSA-N
• SMILES: O=C(N(C(C)C)C(C)C)C1=CC=C(C2=N[C@]3([H])CCN(C)C[C@]3([H])C4=CC(OCC)=C(OC)C=C24)C=C1

Pumafentrine (Cat No.: I035211) is an investigational compound being studied for its potential use in the treatment of neurological disorders, particularly for its ability to modulate neurotransmitter systems. It works by affecting specific receptors in the brain, which may help regulate conditions such as anxiety, depression, and cognitive dysfunction. Preclinical studies suggest pumafentrine may offer therapeutic benefits by improving neuronal communication and brain function. Currently, clinical trials are underway to assess its safety, efficacy, and potential as a treatment for neurological conditions.

Reference

1: Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2014;165(3):152-64. doi: 10.1159/000368800. Epub 2014 Dec 20. Review. PubMed PMID: 25532037.
2: Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. PLoS One. 2013;8(2):e56867. doi: 10.1371/journal.pone.0056867. Epub 2013 Feb 28. PubMed PMID: 23468885; PubMed Central PMCID: PMC3585290.
3: Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, Weissmann N, Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J. 2008 Mar;31(3):599-610. Epub 2007 Nov 21. PubMed PMID: 18032446.